EA201891562A3 - Трифторметиловые спирты как модуляторы roryt - Google Patents
Трифторметиловые спирты как модуляторы rorytInfo
- Publication number
- EA201891562A3 EA201891562A3 EA201891562A EA201891562A EA201891562A3 EA 201891562 A3 EA201891562 A3 EA 201891562A3 EA 201891562 A EA201891562 A EA 201891562A EA 201891562 A EA201891562 A EA 201891562A EA 201891562 A3 EA201891562 A3 EA 201891562A3
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- triftoromethyl
- alcohols
- present
- roryt modulators
- syndrome
- Prior art date
Links
- 150000001298 alcohols Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 108091008778 RORγ2 Proteins 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Настоящее изобретение содержит соединения формулы Iгде X, A, A, A, A, R, Rи Rопределены в спецификации. Настоящее изобретение также содержит способ лечения или облегчения синдрома, расстройства или заболевания, причем указанный синдром, расстройство или заболевание представляет собой ревматоидный артрит или псориаз. Настоящее изобретение также содержит способ модулирования активности RORγt у млекопитающего путем введения терапевтически эффективного количества по меньшей мере одного соединения по п.1 формулы изобретения.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462072563P | 2014-10-30 | 2014-10-30 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EA201891562A2 EA201891562A2 (ru) | 2018-12-28 |
| EA201891562A3 true EA201891562A3 (ru) | 2019-04-30 |
| EA035998B1 EA035998B1 (ru) | 2020-09-10 |
Family
ID=54754732
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201790942A EA033699B1 (ru) | 2014-10-30 | 2015-10-30 | ТРИФТОРМЕТИЛОВЫЕ СПИРТЫ КАК МОДУЛЯТОРЫ RORγt |
| EA201891562A EA035998B1 (ru) | 2014-10-30 | 2015-10-30 | Способ получения замещенных производных тиазола |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201790942A EA033699B1 (ru) | 2014-10-30 | 2015-10-30 | ТРИФТОРМЕТИЛОВЫЕ СПИРТЫ КАК МОДУЛЯТОРЫ RORγt |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US9850236B2 (ru) |
| EP (2) | EP3354651B1 (ru) |
| JP (3) | JP6998204B2 (ru) |
| KR (2) | KR20170078750A (ru) |
| CN (3) | CN112979630A (ru) |
| AR (2) | AR102480A1 (ru) |
| AU (2) | AU2015339087B2 (ru) |
| BR (2) | BR122017023050A2 (ru) |
| CA (1) | CA2965512C (ru) |
| CL (3) | CL2017001042A1 (ru) |
| CO (1) | CO2017005014A2 (ru) |
| CR (2) | CR20170542A (ru) |
| CY (1) | CY1121716T1 (ru) |
| DK (1) | DK3212643T3 (ru) |
| EA (2) | EA033699B1 (ru) |
| EC (1) | ECSP17033054A (ru) |
| ES (2) | ES2858503T3 (ru) |
| GT (1) | GT201700090A (ru) |
| HR (1) | HRP20190900T1 (ru) |
| HU (1) | HUE043624T2 (ru) |
| IL (2) | IL251865A0 (ru) |
| JO (2) | JOP20200117A1 (ru) |
| LT (1) | LT3212643T (ru) |
| MA (1) | MA40873B1 (ru) |
| ME (1) | ME03426B (ru) |
| MX (2) | MX369567B (ru) |
| PE (2) | PE20171649A1 (ru) |
| PH (2) | PH12017500800A1 (ru) |
| PL (1) | PL3212643T3 (ru) |
| PT (1) | PT3212643T (ru) |
| RS (1) | RS58613B1 (ru) |
| SG (2) | SG11201703323PA (ru) |
| SI (1) | SI3212643T1 (ru) |
| SM (1) | SMT201900290T1 (ru) |
| SV (1) | SV2017005429A (ru) |
| TR (1) | TR201907763T4 (ru) |
| TW (2) | TWI705057B (ru) |
| UY (2) | UY36377A (ru) |
| WO (1) | WO2016069974A1 (ru) |
| ZA (3) | ZA201703679B (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201803869A (zh) * | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑 |
| US11230555B2 (en) | 2018-03-12 | 2022-01-25 | Escalier Biosciences B.V. | Bicyclic RORγ modulators |
| US11242350B2 (en) | 2018-03-12 | 2022-02-08 | Escalier Biosciences B.V. | Spirocyclic ROR-gamma modulators |
| US10975037B2 (en) | 2018-06-18 | 2021-04-13 | Janssen Pharmaceutica Nv | Phenyl substituted pyrazoles as modulators of RORγt |
| JP2021529161A (ja) | 2018-06-18 | 2021-10-28 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγｔのモジュレーターとしてのピリジニルピラゾール |
| CN112292183A (zh) | 2018-06-18 | 2021-01-29 | 詹森药业有限公司 | 作为RORγt的调节剂的6-氨基吡啶-3-基吡唑 |
| ES2929140T3 (es) * | 2018-06-18 | 2022-11-25 | Janssen Pharmaceutica Nv | Imidazoles sustituidos con fenilo y piridinilo como moduladores de RORgammat |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
| WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
| CN119528866B (zh) * | 2024-11-28 | 2025-10-17 | 河南农业大学 | 一种含双三氟甲基的香豆素叔醇类化合物及其制备方法和应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL91418A (en) | 1988-09-01 | 1997-11-20 | Rhone Poulenc Agrochimie | (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them |
| JPH10504542A (ja) | 1994-07-27 | 1998-05-06 | ジー．ディー．サール アンド カンパニー | 炎症処置用の置換チアゾール化合物 |
| IL158168A0 (en) | 2001-04-16 | 2004-03-28 | Tanabe Seiyaku Co | 5-membered, nitrogen-containing heterocyclic compounds and pharmaceutical compositions containing the same |
| CA2451981C (en) | 2001-08-13 | 2012-02-21 | Janssen Pharmaceutica N.V. | 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity |
| TWI336697B (en) * | 2003-09-19 | 2011-02-01 | Solvay Pharm Bv | Thiazole derivatives as cannabinoid receptor modulators |
| WO2006124687A1 (en) | 2005-05-12 | 2006-11-23 | University Of Medicine And Dentistry Of New Jersey | Opioid receptor subtype-selective agents |
| GB0518237D0 (en) * | 2005-09-07 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| WO2007087427A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
| WO2008064317A1 (en) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Lipophilic opioid receptor active compounds |
| WO2008064318A2 (en) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Peripheral opioid receptor active compounds |
| WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| MX2011000477A (es) | 2008-07-17 | 2011-03-15 | Bayer Cropscience Ag | Compuestos heterociclicos como pesticidas. |
| EP2417134B1 (en) * | 2009-04-08 | 2017-05-17 | Idenix Pharmaceuticals LLC. | Macrocyclic serine protease inhibitors |
| AR079022A1 (es) | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
| EP2368886A1 (en) * | 2010-03-01 | 2011-09-28 | Phenex Pharmaceuticals AG | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease |
| US9101600B2 (en) | 2010-03-11 | 2015-08-11 | New York University | Compounds as RORγt modulators and uses thereof |
| EP3002008B8 (en) | 2010-03-11 | 2018-10-24 | New York University | Amido compounds as roryt modulators and uses thereof |
| WO2011115892A1 (en) | 2010-03-15 | 2011-09-22 | Griffin Patrick R | Modulators of the retinoic acid receptor-related orphan receptors |
| WO2012027965A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012074547A2 (en) | 2010-11-29 | 2012-06-07 | New York University | STEROID COMPOUNDS AS RORγt MODULATORS AND USES THEREOF |
| WO2012090995A1 (ja) | 2010-12-28 | 2012-07-05 | ライオン株式会社 | 口腔状態の判定方法、並びにそのために用いられる分析用具、装置、及びプログラム |
| WO2012129491A1 (en) | 2011-03-24 | 2012-09-27 | Abbott Laboratories | Trpv3 modulators |
| US9586928B2 (en) | 2011-05-16 | 2017-03-07 | The Scripps Research Institute | Modulators of the nuclear hormone receptor ROR |
| WO2013018695A1 (ja) | 2011-07-29 | 2013-02-07 | 武田薬品工業株式会社 | 複素環化合物 |
| KR20140072090A (ko) | 2011-09-09 | 2014-06-12 | 뉴욕 유니버시티 | ＲＯＲγｔ 조정제로서의 아미도 화합물 및 이의 용도 |
| GB201116641D0 (en) * | 2011-09-27 | 2011-11-09 | Glaxo Group Ltd | Novel compounds |
| EP2800745B1 (en) | 2011-12-02 | 2020-02-12 | Phenex Pharmaceuticals AG | Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
| US20130190356A1 (en) | 2011-12-22 | 2013-07-25 | Genentech, Inc. | Benzyl sulfonamide derivatives as rorc modulators |
| UA117913C2 (uk) * | 2012-05-31 | 2018-10-25 | Фінекс Фармас'Ютікалс Аг | КАРБОКСАМІД- АБО СУЛЬФОНАМІДЗАМІЩЕНІ ТІАЗОЛИ ТА СПОРІДНЕНІ ПОХІДНІ ЯК МОДУЛЯТОРИ ОРФАНОВОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ |
| JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
| PE20151203A1 (es) * | 2012-10-16 | 2015-08-31 | Janssen Pharmaceutica Nv | MODULADORES DE QUINOLINILO UNIDOS A FENILO DE ROR-GAMMA-t |
| US9624210B2 (en) * | 2012-12-12 | 2017-04-18 | Merck Sharp & Dohme Corp. | Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors |
| WO2014195321A1 (en) | 2013-06-04 | 2014-12-11 | Acturum Life Science AB | Triazole compounds and their use as gamma secretase modulators |
| CN103333168B (zh) * | 2013-07-23 | 2015-08-05 | 清华大学 | 一种酰胺类化合物及其制备方法与应用 |
| US9663469B2 (en) | 2013-09-09 | 2017-05-30 | Bristol-Myers Squibb Company | RORγ modulators |
| US20150072890A1 (en) | 2013-09-11 | 2015-03-12 | 20/20 Gene Systems, Inc. | Methods and compositions for aiding in the detection of lung cancer |
| US9725443B2 (en) | 2013-09-20 | 2017-08-08 | Bristol-Myers Squibb Company | RORγ modulators |
| AU2014334619A1 (en) * | 2013-10-15 | 2016-04-21 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORyt |
| BR112016008257A2 (pt) * | 2013-10-15 | 2017-09-26 | Janssen Pharmaceutica Nv | moduladores de roryt de álcool quinolínico secundário |
| JP6461960B2 (ja) | 2013-12-05 | 2019-01-30 | リード ファーマ ホールディング ビー．ブイ． | ＲＯＲガンマ（γ）モジュレータ |
| WO2015103507A1 (en) | 2014-01-06 | 2015-07-09 | Bristol-Myers Squibb Company | Cyclohexyl sulfone rorϒ modulators |
| US9637455B2 (en) | 2014-01-06 | 2017-05-02 | Bristol-Myers Squibb Company | Heterocyclic sulfone RORγ modulators |
| US20160326108A1 (en) | 2014-01-06 | 2016-11-10 | Bristol-Myers Squibb Company | Pyrrolidinyl sulfone derivatives and their use as ror gamma modulators |
| CN106132931B (zh) | 2014-01-06 | 2019-08-02 | 百时美施贵宝公司 | 碳环砜RORγ调节剂 |
| EP3122721A4 (en) | 2014-03-27 | 2018-01-10 | Piramal Enterprises Limited | Ror-gamma modulators and uses thereof |
| ES2767303T3 (es) | 2014-10-30 | 2020-06-17 | Janssen Pharmaceutica Nv | Tiazoles sustituidos por amida como moduladores de Rorgamma T |
| TR201820513T4 (tr) | 2014-10-30 | 2019-02-21 | Janssen Pharmaceutica Nv | Roryt modülatörleri olarak tiazoller. |
-
2014
- 2014-10-30 JO JOP/2020/0117A patent/JOP20200117A1/ar unknown
-
2015
- 2015-10-28 TW TW108110613A patent/TWI705057B/zh not_active IP Right Cessation
- 2015-10-28 TW TW104135342A patent/TWI667230B/zh not_active IP Right Cessation
- 2015-10-29 MA MA40873A patent/MA40873B1/fr unknown
- 2015-10-29 JO JOP/2015/0267A patent/JO3571B1/ar active
- 2015-10-30 CR CR20170542A patent/CR20170542A/es unknown
- 2015-10-30 WO PCT/US2015/058193 patent/WO2016069974A1/en not_active Ceased
- 2015-10-30 JP JP2017523358A patent/JP6998204B2/ja not_active Expired - Fee Related
- 2015-10-30 US US14/927,499 patent/US9850236B2/en not_active Expired - Fee Related
- 2015-10-30 SG SG11201703323PA patent/SG11201703323PA/en unknown
- 2015-10-30 CA CA2965512A patent/CA2965512C/en active Active
- 2015-10-30 PE PE2017000795A patent/PE20171649A1/es unknown
- 2015-10-30 CN CN202110007104.5A patent/CN112979630A/zh active Pending
- 2015-10-30 BR BR122017023050A patent/BR122017023050A2/pt not_active Application Discontinuation
- 2015-10-30 KR KR1020177014519A patent/KR20170078750A/ko not_active Ceased
- 2015-10-30 HU HUE15802227A patent/HUE043624T2/hu unknown
- 2015-10-30 ES ES18160676T patent/ES2858503T3/es active Active
- 2015-10-30 SM SM20190290T patent/SMT201900290T1/it unknown
- 2015-10-30 PL PL15802227T patent/PL3212643T3/pl unknown
- 2015-10-30 CR CR20170166A patent/CR20170166A/es unknown
- 2015-10-30 CN CN201711211144.1A patent/CN107827841A/zh active Pending
- 2015-10-30 MX MX2018004348A patent/MX369567B/es unknown
- 2015-10-30 PE PE2017002473A patent/PE20180250A1/es unknown
- 2015-10-30 ME MEP-2019-118A patent/ME03426B/me unknown
- 2015-10-30 TR TR2019/07763T patent/TR201907763T4/tr unknown
- 2015-10-30 BR BR112017008816A patent/BR112017008816A2/pt not_active Application Discontinuation
- 2015-10-30 EP EP18160676.5A patent/EP3354651B1/en active Active
- 2015-10-30 CN CN201580071983.0A patent/CN107108599A/zh active Pending
- 2015-10-30 RS RS20190495A patent/RS58613B1/sr unknown
- 2015-10-30 AU AU2015339087A patent/AU2015339087B2/en not_active Ceased
- 2015-10-30 SG SG10201805355YA patent/SG10201805355YA/en unknown
- 2015-10-30 LT LTEP15802227.7T patent/LT3212643T/lt unknown
- 2015-10-30 UY UY0001036377A patent/UY36377A/es unknown
- 2015-10-30 EA EA201790942A patent/EA033699B1/ru not_active IP Right Cessation
- 2015-10-30 KR KR1020177032857A patent/KR20170127580A/ko not_active Ceased
- 2015-10-30 DK DK15802227.7T patent/DK3212643T3/da active
- 2015-10-30 PT PT15802227T patent/PT3212643T/pt unknown
- 2015-10-30 AR ARP150103522A patent/AR102480A1/es unknown
- 2015-10-30 EP EP15802227.7A patent/EP3212643B1/en active Active
- 2015-10-30 SI SI201530677T patent/SI3212643T1/sl unknown
- 2015-10-30 ES ES15802227T patent/ES2724556T3/es active Active
- 2015-10-30 EA EA201891562A patent/EA035998B1/ru not_active IP Right Cessation
- 2015-10-30 HR HRP20190900TT patent/HRP20190900T1/hr unknown
- 2015-10-30 MX MX2017005689A patent/MX367912B/es active IP Right Grant
-
2017
- 2017-04-23 IL IL251865A patent/IL251865A0/en unknown
- 2017-04-27 CL CL2017001042A patent/CL2017001042A1/es unknown
- 2017-04-27 PH PH12017500800A patent/PH12017500800A1/en unknown
- 2017-04-28 GT GT201700090A patent/GT201700090A/es unknown
- 2017-04-28 SV SV2017005429A patent/SV2017005429A/es unknown
- 2017-05-19 CO CONC2017/0005014A patent/CO2017005014A2/es unknown
- 2017-05-29 ZA ZA2017/03679A patent/ZA201703679B/en unknown
- 2017-05-30 EC ECIEPI201733054A patent/ECSP17033054A/es unknown
- 2017-07-31 US US15/664,673 patent/US10150762B2/en active Active
- 2017-11-08 AR ARP170103107A patent/AR110155A2/es unknown
- 2017-11-14 IL IL255648A patent/IL255648B/en active IP Right Grant
- 2017-11-20 PH PH12017502105A patent/PH12017502105A1/en unknown
- 2017-12-14 UY UY0001037517A patent/UY37517A/es unknown
-
2018
- 2018-02-16 CL CL2018000436A patent/CL2018000436A1/es unknown
- 2018-08-31 ZA ZA201805861A patent/ZA201805861B/en unknown
- 2018-08-31 ZA ZA201805860A patent/ZA201805860B/en unknown
- 2018-10-25 JP JP2018200608A patent/JP6623270B2/ja not_active Expired - Fee Related
-
2019
- 2019-01-14 AU AU2019200228A patent/AU2019200228B2/en not_active Ceased
- 2019-06-04 CL CL2019001514A patent/CL2019001514A1/es unknown
- 2019-06-14 CY CY20191100620T patent/CY1121716T1/el unknown
-
2020
- 2020-06-18 JP JP2020104927A patent/JP2020180129A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201590736A1 (ru) | СВЯЗАННЫЕ С МЕТИЛЕНОМ ХИНОЛИНИЛОВЫЕ МОДУЛЯТОРЫ RORγt | |
| EA201891562A3 (ru) | Трифторметиловые спирты как модуляторы roryt | |
| EA201590750A1 (ru) | СВЯЗАННЫЕ С ФЕНИЛОМ ХИНОЛИНИЛОВЫЕ МОДУЛЯТОРЫ RORγT | |
| EA201892438A1 (ru) | 6-АМИНОПИРИДИН-3-ИЛТИАЗОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγt | |
| EA201692204A1 (ru) | Композиции и способы модулирования экспрессии фактора комплемента b | |
| MX381417B (es) | Inhibidores de glucosidasa. | |
| MX372543B (es) | Moduladores de receptor nuclear. | |
| JOP20210050A1 (ar) | معدلات تعبير pnpla3 | |
| HK1213250A1 (zh) | RORγT的雜芳基連接的喹啉基調節劑 | |
| BR112016008258A2 (pt) | moduladores de ror?t de quinolinila | |
| CY1121285T1 (el) | Θειαζολια ως διαμορφωτες toy roryt | |
| BR112017008852A2 (pt) | tiazóis substituídos com amida como moduladores do roryt | |
| BR112014026160A2 (pt) | métodos para tratar intolerância à lactose | |
| BR112016008215A2 (pt) | moduladores de quinolinila ligados por alquila de roryt | |
| BR112016008257A2 (pt) | moduladores de roryt de álcool quinolínico secundário | |
| WO2015057200A8 (en) | Heteroaryl linked quinolinyl modulators of rorϒt | |
| BR112016008183A2 (pt) | Moduladores de ror-gama-t de quinolinila ligados à fenila | |
| UA114009C2 (xx) | Зв'язані з метиленом хінолінільні модулятори ror-гamma-t |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |